1. Home
  2. TMP vs MLYS Comparison

TMP vs MLYS Comparison

Compare TMP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMP
  • MLYS
  • Stock Information
  • Founded
  • TMP 1836
  • MLYS 2019
  • Country
  • TMP United States
  • MLYS United States
  • Employees
  • TMP N/A
  • MLYS N/A
  • Industry
  • TMP Major Banks
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • TMP Finance
  • MLYS Health Care
  • Exchange
  • TMP Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • TMP 970.5M
  • MLYS 890.6M
  • IPO Year
  • TMP N/A
  • MLYS 2023
  • Fundamental
  • Price
  • TMP $61.62
  • MLYS $13.02
  • Analyst Decision
  • TMP Buy
  • MLYS Strong Buy
  • Analyst Count
  • TMP 2
  • MLYS 4
  • Target Price
  • TMP $69.00
  • MLYS $27.00
  • AVG Volume (30 Days)
  • TMP 50.1K
  • MLYS 674.9K
  • Earning Date
  • TMP 07-25-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • TMP 3.98%
  • MLYS N/A
  • EPS Growth
  • TMP 457.40
  • MLYS N/A
  • EPS
  • TMP 5.55
  • MLYS N/A
  • Revenue
  • TMP $306,372,000.00
  • MLYS N/A
  • Revenue This Year
  • TMP $16.18
  • MLYS N/A
  • Revenue Next Year
  • TMP $6.47
  • MLYS N/A
  • P/E Ratio
  • TMP $11.24
  • MLYS N/A
  • Revenue Growth
  • TMP 39.13
  • MLYS N/A
  • 52 Week Low
  • TMP $53.41
  • MLYS $8.24
  • 52 Week High
  • TMP $79.01
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • TMP 40.34
  • MLYS 41.04
  • Support Level
  • TMP $62.05
  • MLYS $12.83
  • Resistance Level
  • TMP $63.70
  • MLYS $13.70
  • Average True Range (ATR)
  • TMP 1.92
  • MLYS 0.73
  • MACD
  • TMP -0.51
  • MLYS -0.09
  • Stochastic Oscillator
  • TMP 4.50
  • MLYS 6.03

About TMP Tompkins Financial Corporation

Tompkins Financial Corp is a Financial Holding Company. It has three business segments, consisting of banking, insurance and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Insurance is comprised of property and casualty insurance services and employee benefit consulting. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates majority of its revenue from Banking segment.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: